Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
An Open-label, Multi-center Rollover Protocol for Continued Characterization of Safety and Tolerability for Subjects Who Have Participated in a Novartis-sponsored Spartalizumab Study as Single Agent or in Combination With Other Study Treatments
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Novartis Pharmaceuticals
- Phone Number: 1-888-669-6682
- Email: novartis.email@novartis.com
Study Contact Backup
- Name: Novartis Pharmaceuticals
- Phone Number: +41613241111
Study Locations
-
-
-
Leuven, Belgium, 3000
- Novartis Investigative Site
-
Liège, Belgium, 4000
- Novartis Investigative Site
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Novartis Investigative Site
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Novartis Investigative Site
-
-
-
-
-
Guangzhou, China, 510060
- Novartis Investigative Site
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510515
- Novartis Investigative Site
-
-
-
-
-
Brno, Czechia, 656 53
- Novartis Investigative Site
-
-
-
-
-
Lille, France, 59037
- Novartis Investigative Site
-
Lyon, France, 69373
- Novartis Investigative Site
-
Marseille, France, 13273
- Novartis Investigative Site
-
Marseille, France, 13885
- Novartis Investigative Site
-
Villejuif, France, 94800
- Novartis Investigative Site
-
-
-
-
-
Essen, Germany, 45147
- Novartis Investigative Site
-
Heidelberg, Germany, 69120
- Novartis Investigative Site
-
Ulm, Germany, 89081
- Novartis Investigative Site
-
-
Thuringia
-
Jena, Thuringia, Germany, 07740
- Novartis Investigative Site
-
-
-
-
-
High West, Hong Kong, 999077
- Novartis Investigative Site
-
Hong Kong, Hong Kong, 999077
- Novartis Investigative Site
-
-
Hong Kong
-
Hong Kong, Hong Kong, Hong Kong, 999077
- Novartis Investigative Site
-
-
-
-
-
Budapest, Hungary, H 1122
- Novartis Investigative Site
-
-
Hajdu Bihar Megye
-
Debrecen, Hajdu Bihar Megye, Hungary, 4032
- Novartis Investigative Site
-
-
-
-
-
Naples, Italy, 80131
- Novartis Investigative Site
-
-
MI
-
Milan, MI, Italy, 20133
- Novartis Investigative Site
-
Milan, MI, Italy, 20141
- Novartis Investigative Site
-
Milan, MI, Italy, 20132
- Novartis Investigative Site
-
Rozzano, MI, Italy, 20089
- Novartis Investigative Site
-
-
MO
-
Modena, MO, Italy, 41124
- Novartis Investigative Site
-
-
PN
-
Aviano, PN, Italy, 33081
- Novartis Investigative Site
-
-
SI
-
Siena, SI, Italy, 53100
- Novartis Investigative Site
-
-
-
-
South Holland
-
Leiden, South Holland, Netherlands, 2333 ZA
- Novartis Investigative Site
-
-
-
-
-
Gdansk, Poland, 80-214
- Novartis Investigative Site
-
Poznan, Poland, 60-693
- Novartis Investigative Site
-
-
-
-
-
Seoul, South Korea, 05505
- Novartis Investigative Site
-
-
Seoul
-
Seoul, Seoul, South Korea, 03080
- Novartis Investigative Site
-
-
-
-
-
Barcelona, Spain, 08035
- Novartis Investigative Site
-
Barcelona, Spain, 08036
- Novartis Investigative Site
-
Madrid, Spain, 28034
- Novartis Investigative Site
-
Madrid, Spain, 28009
- Novartis Investigative Site
-
Valencia, Spain, 46010
- Novartis Investigative Site
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, Spain, 08907
- Novartis Investigative Site
-
-
-
-
-
Zurich, Switzerland, 8091
- Novartis Investigative Site
-
-
-
-
-
Taipei, Taiwan, 10002
- Novartis Investigative Site
-
-
-
-
-
Bangkok, Thailand, 10330
- Novartis Investigative Site
-
Chiang Mai, Thailand, 50200
- Novartis Investigative Site
-
-
Hat Yai
-
Songkhla, Hat Yai, Thailand, 90110
- Novartis Investigative Site
-
-
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
-
Oregon
-
Portland, Oregon, United States, 97123
- Providence Portland Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center Uni of Te
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject is currently enrolled in a pre-defined Novartis-sponsored study and is receiving spartalizumab as single agent or in combination with other study treatment,
- Subject is currently deriving clinical benefit from the study treatment, as determined by the investigator.
Other protocol defined inclusion criteria may apply
Exclusion Criteria:
- Subject has been permanently discontinued from spartalizumab in the parent protocol for any reason other than enrollment in the Roll over Study
- Subject does not meet the criteria specified in the parent protocol criteria for continued study treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: PDR001
All subjects in all combination will be entered in one arm
|
PDR001
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Frequency and nature of AE and SAE by subject
Time Frame: 5 years
|
Safety data.
|
5 years
|
|
Number of subjects with PDR001 dose interruption and/or reduction
Time Frame: 5 years
|
5 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of subjects receiving PDR001
Time Frame: 5 years
|
5 years
|
|
Subject's exposure duration
Time Frame: 5 years
|
5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CPDR001X2X01B
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.